Novartis Stock Borsa Italiana
Stocks
NOVN
CH0012005267
Pharmaceuticals
OTC Markets Traded| Market Cap | 284B 248B 229B 211B 398B 27,326B 406B 2,735B 1,076B 13,383B 1,066B 1,042B 46,070B | P/E 2026 * |
21.7x | P/E 2027 * | 18.3x |
|---|---|---|---|---|---|
| Enterprise Value | 316B 276B 255B 235B 442B 30,407B 452B 3,043B 1,197B 14,892B 1,186B 1,160B 51,266B | EV / Sales 2026 * |
5.55x | EV / Sales 2027 * | 5.18x |
| Free-Float |
91.66% | Yield 2026 * |
2.84% | Yield 2027 * | 2.93% |
Last Transcript: Novartis
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 2018-01-31 | |
Mukul Mehta
DFI | Director of Finance/CFO | - | 2026-03-15 |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 64 | 2022-05-15 |
| Director | Title | Age | Since |
|---|---|---|---|
Nancy Andrews
BRD | Director/Board Member | 67 | 2014-12-31 |
| Director/Board Member | 69 | 2015-12-31 | |
Ton Büchner
BRD | Director/Board Member | 61 | 2015-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -2.58% | - | - | 284B | |
| +0.85% | -0.80% | +52.79% | +161.33% | 1,051B | |
| +1.23% | -1.53% | +54.58% | +59.08% | 609B | |
| +0.04% | +2.58% | +34.47% | +86.33% | 450B | |
| +0.78% | -0.71% | +29.28% | +24.10% | 330B | |
| -0.27% | -1.87% | +22.34% | +22.51% | 263B | |
| -1.76% | +2.37% | -20.43% | -38.00% | 223B | |
| -1.42% | +0.80% | +24.27% | +57.50% | 198B | |
| -1.48% | +3.43% | +24.08% | +71.67% | 167B | |
| -0.36% | +3.64% | +2.37% | -30.88% | 143B | |
| Average | -0.24% | +0.88% | +24.86% | +45.96% | 381.56B | |
| Weighted average by Cap. | +0.24% | +0.13% | +36.22% | +78.25% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 56.91B 49.73B 45.89B 42.3B 79.72B 5,480B 81.49B 548B 216B 2,684B 214B 209B 9,239B | 60.31B 52.71B 48.64B 44.83B 84.5B 5,808B 86.37B 581B 229B 2,845B 227B 222B 9,792B |
| Net income | 14.08B 12.3B 11.35B 10.47B 19.72B 1,356B 20.16B 136B 53.37B 664B 52.87B 51.71B 2,286B | 15.64B 13.67B 12.61B 11.63B 21.92B 1,506B 22.4B 151B 59.3B 738B 58.75B 57.46B 2,540B |
| Net Debt | 32B 27.96B 25.8B 23.78B 44.83B 3,081B 45.82B 308B 121B 1,509B 120B 118B 5,195B | 28.48B 24.89B 22.97B 21.17B 39.9B 2,743B 40.79B 275B 108B 1,343B 107B 105B 4,624B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
